Innovative Therapies on the Horizon to Treat AMD
Carl Regillo, MD and Diana Do, MD react to newer therapies being explored for wet AMD and discuss their place in future therapeutic algorithms.
Intravitreal Gene Therapy for Wet AMD
An overview of new gene therapy options for wet AMD that are currently being explored in clinical trials.
Faricimab: A New Bispecific Antibody with Promising Durability in AMD
Results of recent phase III clinical trials with respect to efficacy and safety of faricimab, an investigational bispecific antibody which inhibits both VEGF-A and angiopoietin-2.
Port Delivery System for AMD: Patient Selection and Safety Insights
Retina specialists provide insight into the patient selection and safety concerns with the innovative Port Delivery System (PDS) that offers a new means of sustained anti-VEGF therapy.
The Port Delivery System: A Novel Sustained Release Treatment Option in AMD
Carl Regillo, MD highlights the Port Delivery System (PDS), a new surgical implant with sustained release of anti-VEGF therapy that recently completed phase III clinical trials.
Brolucizumab Safety Signal: Impact on Practice
Carl Regillo, MD and Diana Do, MD discuss the safety concerns with the use of brolucizumab in wet AMD and the impact of these concerns in their practice.
Treat and Extend Approach to Anti-VEGF Therapy for AMD
An overview of standard anti-VEGF treatments for wet AMD and recommendations for individualizing patient therapy with a treat and extend approach.
Imaging Modalities in Wet AMD
Role of imaging modalities in the diagnosis and monitoring of age-related macular degeneration (AMD).
Differentiating Between Wet and Dry AMD
Carl Regillo, MD and Diana Do, MD, describe the progressive nature of age-related macular degeneration (AMD) and differences between dry AMD and wet AMD.
2 Clarke Drive Cranbury, NJ 08512